1. Making Women's Lives Better
Contact Person: Dr. Meir Teichner, CEO Phone: +972-(0)54-726-9232 Email: info@la-gradelle.com
Over 1.3 billion women suffer from urinary incontinence and/or genital prolapse
worldwide (IPFD, 2007; Vos, 2012; Medtech Insight, 2014).
Gynotech's non-surgical non-drug self-inserted, self-adjustable vaginal ring
pessary “GynoPess™” fully addresses urinary incontinence (i.e. involuntary escape
of urine) and genital prolapse.
Company Status
Gynotech obtained a
U.S. patent (# US
7,036,511 B2) and an
Israeli patent (#
146534) on the self-
adjustable vaginal ring.
Road Map- By mid-2016
GynoPess™ ready for
clinical trials. By end-2017
clinical trials and FDA 510K
approval.
Commercialization during
2018.
Time to market is
estimated to be around 3
years with sales ramping
up from 2018.
Silent Epidemics: Urinary Incontinence and Genital Prolapse
27.6% of all women, i.e. 1 billion women, suffer from urinary incontinence (IPFD,
2007). Genital prolapse occurs when the pelvic organs fall from their normal position
into or through the vagina, causing discomfort, pain and discharge, which may also
coexist with incontinence. 9.3% of all women, i.e. 316 million women, suffer
from genital prolapse (Vos, 2012). Despite the high prevalence, current solutions are
unhelpful: Surgery to address urinary incontinence cannot be carried out while a
woman is still in her pregnancies period - only 70% of women who can and are
willing to be operated on are successful; expensive absorbent pads/garments
can cause skin irritation/breakdown/infection and are not covered by insurers since
they are personal hygiene products; drugs are overused with side effects; and
different shapes/sizes pessary devices are used but are unhelpful, requiring
time/effort to insert/fit into the vagina and the repeated assistance of a doctor,
causing the woman embarrassment and more expenses.
GynoPess™: One Size for All
GynoPess™ has several distinct advantages:
 Easy to insert since it does not use complicated adjusting mechanisms, it requires
little time and effort to insert and fit into the vagina as well as to remove there
from. There are no visits to the doctor and it can be bought OTC (Over the
Counter). The user can insert, remove and fit it herself, enabling a more sensitive
and comfortable insertion/removal, no need for absorbent pads/garments, all done
in private. Thus, there is no pain and no additional expenses.
 Improving women's quality of life by sparing the inconvenience, the limitation
of daily activity and the shame/embarrassment due to the receipt of professional
assistance, e.g. from a doctor. It also prevents smell, irritation and infection.
 Eliminating the need for surgery or drugs, using Gynotech, young women will
not need a surgical procedure, even after childbirth age, nor will they need drugs.
 Saving costs since it will eliminate the necessity to buy and try several pessary
shapes and sizes, before finding the one that is most comfortable and most
effective. It will also save the costs of repeated professional assistance.
Management Team
Dr. Meir Teichner
CEO (D.Sc. in biochemistry
and pharmacology) - He
served for 20 years as CEO
of Israeli and Canadian hi-
tech companies, including
CEO of 2 technological
incubators. Earlier, he was
a senior executive at ICL
(Israel Chemical Ltd.)
Group.
Dr. Abraham Nissenkorn
CMO and Founder (M.D.) -
He is the inventor of
GynoPess™ the adjustable
ring pessary for
treating/preventing female
urinary incontinence and
pelvic organ prolapse,
based on his 30 years of
experience as a
gynecologist.
Initial Target Market: USA
In the USA, 19-20 million women suffer from urinary incontinence and 3.3 million
women suffer from genital prolapse. The U.S. female urinary incontinence therapies
market reached $1.3 billion (Medtech Insight, 2014). $19.5 billion was spent on
urinary incontinence care and it accounts for 6% of nursing home admissions for
elderly women, costing $3 billion (American College of Physicians, 2014).
Business Model: U.S. Distributors
In the USA, Gynotech will focus on selling its products through tier-1 distributors.
Distributors’ price for consumers (women) is conservatively estimated at $20 per unit
(although it could be $30). Gynotech’s FOB (Free on Board) price will be $10 per unit
while its COGS (Cost of Goods Sold) are also conservatively estimated at $4 per unit.
Investment Sought
Gynotech is seeking $1 million (as part of its $3 million round) to (i) Complete
product development, (ii) perform clinical trial, (iii) obtain the necessary regulatory
approvals, (iv) begin manufacturing and distribution (v) build its team, including a
U.S.-based CEO, and strengthen its intellectual property portfolio.